Unknown

Dataset Information

0

Sacubitril/valsartan reduces cardiac decompensation in heart failure with preserved ejection fraction: a meta-analysis.


ABSTRACT:

Background

The impact of sacubitril-valsartan on heart failure (HF) patients with preserved ejection fractions (HFpEF) is uncertain. The purpose of this meta-analysis was to explore the clinical advantages and safety of sacubitril-valsartan in patients with HFpEF.

Methods

PubMed and Web of Science were searched without any restrictions from inception to 8 May 2022 to identify valuable articles. The studies that met the inclusion criteria were analyzed.

Results

Four trials, with a total of 7008 patients were included. Compared with valsartan, sacubitril-valsartan significantly reduced the rate of HF decompensation and of the combined end point of HF decompensation and all-cause mortality. All-cause mortality, New York Heart Association class improvement and rate of hyperkalemia were not significantly different between the two groups. Regarding safety, sacubitril-valsartan was more likely to increase the risk of hypotension.

Conclusion

This meta-analysis suggests that sacubitril-valsartan may be an effective strategy to reduce HF decompensation events in patients with HFpEF.Systematic Review registration: CRD42022336077.

SUBMITTER: Basile C 

PROVIDER: S-EPMC9794138 | biostudies-literature | 2023 Jan

REPOSITORIES: biostudies-literature

altmetric image

Publications

Sacubitril/valsartan reduces cardiac decompensation in heart failure with preserved ejection fraction: a meta-analysis.

Basile Christian C   Paolillo Stefania S   Gargiulo Paola P   Marzano Federica F   Asile Gaetano G   Parlati Antonio Luca Maria ALM   Chirico Alfonsina A   Nardi Ermanno E   Buonocore Davide D   Colella Angela A   Perrone-Filardi Pasquale P  

Journal of cardiovascular medicine (Hagerstown, Md.) 20221115 1


<h4>Background</h4>The impact of sacubitril-valsartan on heart failure (HF) patients with preserved ejection fractions (HFpEF) is uncertain. The purpose of this meta-analysis was to explore the clinical advantages and safety of sacubitril-valsartan in patients with HFpEF.<h4>Methods</h4>PubMed and Web of Science were searched without any restrictions from inception to 8 May 2022 to identify valuable articles. The studies that met the inclusion criteria were analyzed.<h4>Results</h4>Four trials,  ...[more]

Similar Datasets

| S-EPMC10804200 | biostudies-literature
| S-EPMC7944492 | biostudies-literature
| S-EPMC8109279 | biostudies-literature
| S-EPMC8649234 | biostudies-literature
| S-EPMC9288803 | biostudies-literature
| S-EPMC8255468 | biostudies-literature
| S-EPMC8121351 | biostudies-literature
| S-EPMC10092840 | biostudies-literature
| S-EPMC8455346 | biostudies-literature
| S-EPMC6554586 | biostudies-literature